Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 8, 2011, Pages 1426-1435

  Ocak, Meltem ^a,b   Helbok, Anna ^a   Rangger, Christine ^a   Peitl, Petra Kolenc ^c   Nock, Berthold A ^d   Morelli, Giancarlo ^e   Eek, Annemarie ^f   Sosabowski, Jane K ^g   Breeman, Wout A P ^h   Reubi, Jean Claude ⁱ   Decristoforo, Clemens ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b ISTANBUL UNIVERSITY   (Turkey)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

177Lu; CCK; Cholecystokinin receptor; Gastrin; In vitro stability; In vivo stability; Metabolism

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CHOLECYSTOKININ B RECEPTOR; GASTRIN DERIVATIVE; PEPTIDE; RADIOLIGAND;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN METABOLISM; SERUM; THYROID MEDULLARY CARCINOMA; TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; COOPERATIVE BEHAVIOR; FEMALE; HUMANS; METHIONINE; MICE; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; PEPTIDES; PROTEIN BINDING; PROTEIN STABILITY; RECEPTOR, CHOLECYSTOKININ B;

EID: 80052579110     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1818-9     Document Type: Article

References (26)

1. Breeman WA, Kwekkeboom DJ, de Blois E, de Jong M, Visser TJ, Krenning EP. Radiolabelled regulatory peptides for imaging and therapy. Anticancer Agents Med Chem 2007;7 (3):345-57. (Pubitemid 46813470)
2. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med 2008;49(11):1735-8.
3. Behr TM, Jenner N, Radetzky S, Béhé M, Gratz S, Yücekent S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998;25:424-30. (Pubitemid 28211607)
4. de Jong M, Bakker WH, Bernard BF, Valkema R, Kwekkeboom DJ, Reubi JC, et al. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: A peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999;40:2081-7. (Pubitemid 30022025)
5. Reubi JC, Schaer JC, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997;57 (7):1377-86. (Pubitemid 27152565)
6. Behr TM, Béhé MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary throid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002;32(2):97-109. (Pubitemid 34311076)
7. Aloj L, Caracó C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, et al. In vitro and in vivo evaluation of 111In-DTPAGlu-GCCK8 for cholecystokinin-B receptor imaging. J Nucl Med 2004;45(3):485-94. (Pubitemid 47618625)
8. von Guggenberg E, Béhé M, Behr TM, Saurer M, Seppi T, Decristoforo C. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin. Bioconjug Chem 2004;15(4):864-71. (Pubitemid 38981962)
9. Nock BA, Maina T, Béhé M, Nikolopoulou A, Gotthardt M, Schmitt JS, et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med 2005;46 (10):1727-36. (Pubitemid 46211597)
10. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 2007;48 (4):615-22. (Pubitemid 47571419)
11. Breeman WA, Fröberg AC, de Blois E, van Gameren A, Melis M, de Jong M, et al. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol 2008;35(8):839-49.
12. Roosenburg S, Laverman P, Joosten L, Eek A, Oyen WJ, de Jong M, et al. Stabilized (111)In-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: Synthesis and evaluation. Bioconjug Chem 2010;21(4):663-70.
13. Görges R, Kahaly G, Müller-Brand J, Mäcke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001;11(7):647-59. (Pubitemid 32701585)
14. Aloj L, Morelli G. Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy. Curr Pharm Des 2004;10(24):3009-31. (Pubitemid 39214008)
15. Gotthardt M, Boermann OC, Behr TM, Béhé MP, Oyen WJ. Development and clinical application of peptide-based radiopharmaceuticals. Curr Pharm Des 2004;10(24):2951-63. (Pubitemid 39214004)
16. de Jong M, Verwijnen SM, de Visser M, Kwekkeboom DJ, Valkema R, Krenning EP. Peptides for radionuclide therapy. In: Stigbrand T, Carlsson J, Adams GP, editors. Targeted radionuclide tumor therapy, biological aspects. New York: Springer; 2008. p. 117-44.
17. Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D, et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 2002;29 (4):431-42. (Pubitemid 34597115)
18. Harrison A, Walker CA, Parker D, Jankowski KJ, Cox JP, Craig AS, et al. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Int J Rad Appl Instrum B 1991;18:469-76.
19. Liu S, Edwards DS. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem 2001;12:7-34. (Pubitemid 32113652)
20. Good S, Walter MA, Waser B, Wang X, Müller-Brand J, Béhé MP, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptorexpressing tumours. Eur J Nucl Med Mol Imaging 2008;35 (10):1868-77.
21. Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006;30 (4):351-67. (Pubitemid 43886897)
22. Adessi C, Soto C. Converting a peptide into a drug: Strategies to improve stability and bioavailability. Curr Med Chem 2002;9 (9):963-78. (Pubitemid 34498572)
23. Ocak M, Helbok A, von Guggenberg E, Ozsoy Y, Kabasakal L, Kremser L, et al. Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative. Nucl Med Biol 2011;38(2):171-9.
24. Konkoy CS, Davis TP. Ectoenzymes as sites of peptide regulation. Trends Pharmacol Sci 1996;17(8):288-94. (Pubitemid 26261893)
25. Pauwels S, Najdovski T, Dimaline R, Lee CM, Deschodt-Lanckman M. Degradation of human gastrin and CCK by endopeptides 24.11: Differential behaviour of the sulphated and unsulphated peptides. Biochim Biophys Acta 1989;996(1-2):82-8. (Pubitemid 19152727)
26. Martinez J, Rodriguez M, Bali JP, Laur J. Phenethyl ester derivative analogues of the C-terminal tetrapeptide of gastrin as potent gastrin antagonists. J Med Chem 1986;29(11):2201-6. (Pubitemid 17182294)